Loading
Loading
Research Overview
Endogenous androgenic steroid hormone. Binds the androgen receptor (AR) to upregulate nitrogen retention, muscle protein synthesis, and red blood cell production. Aromatised to oestradiol by aromatase (CYP19) in adipose, bone, and brain tissue — influences mood, bone density, lipid metabolism, and libido. Reduced to dihydrotestosterone (DHT) by 5-alpha-reductase in androgen-target tissues (prostate, skin, scalp).
Testosterone is a 19-carbon steroid hormone synthesised primarily in the Leydig cells of the testes in male physiology, with smaller contributions from adrenal cortex and ovarian theca cells. It is the parent molecule of the anabolic-androgenic steroid family — every synthetic AAS is structurally derived from or referenced against testosterone.
Exogenous testosterone has been studied in clinical research for over seven decades. Documented research applications include treatment of male hypogonadism, gender-affirming hormone therapy, sarcopenia, osteoporosis, HIV-associated wasting, and post-surgical recovery. It is also the most-studied compound in performance enhancement research literature, with hundreds of trials examining effects on muscle mass, strength, body composition, and athletic performance.
Testosterone is supplied in multiple ester preparations — propionate, enanthate, cypionate, undecanoate, and unesterified suspension — which differ markedly in plasma half-life and dosing frequency. All ester forms hydrolyse in vivo to free testosterone; the ester chain controls release kinetics from the injection depot.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, testosterone has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Testosterone research is most relevant to protocols examining:
Androgen biology and steroidogenesis research
Hypogonadism and TRT clinical research
Comparative AAS pharmacology
testosterone is the reference compound
Bone density and muscle protein synthesis studies
Gender-affirming care research
HPG axis suppression and recovery investigations
Initial phase
Effects begin quickly. Initial signalling starts within the first few days. Start at the lowest dose and assess tolerance.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: Ester-dependent: Propionate ~2 days; Enanthate ~8 days; Cypionate ~8 days; Undecanoate ~21 days (oily depot); Suspension ~24 hours (no ester)). Review data, confirm baseline recovery before any repeat protocol.
Endogenous androgenic steroid hormone. Binds the androgen receptor (AR) to upregulate nitrogen retention, muscle protein synthesis, and red blood cell production. Aromatised to oestradiol by aromatase (CYP19) in adipose, bone, and brain tissue — influences mood, bone density, lipid metabolism, and libido. Reduced to dihydrotestosterone (DHT) by 5-alpha-reductase in androgen-target tissues (prostate, skin, scalp).
| Parameter | Value |
|---|---|
| Dose range | Research literature range: TRT clinical 100–200 mg/week IM (enanthate/cypionate) |
| Alt. dose 2 | supraphysiological research protocols 250–1,000 mg/week documented |
| Schedule | Ester-dependent: Propionate every 1–2 days; Enanthate/Cypionate weekly or twice weekly; Undecanoate (Aveed) every 10 weeks |
| Route | Intramuscular, Subcutaneous, Transdermal, Oral (undecanoate), Buccal, Pellet implant |
| Half-life | Ester-dependent: Propionate ~2 days; Enanthate ~8 days; Cypionate ~8 days; Undecanoate ~21 days (oily depot); Suspension ~24 hours (no ester) |
full shutdown of endogenous LH/FSH/testosterone production
gynaecomastia, water retention, mood changes
typically HDL suppression, variable LDL response
Anticoagulants (warfarin): testosterone potentiates anticoagulation
INR monitoring essential; bleeding risk elevated
Insulin / oral hypoglycaemics: testosterone improves insulin sensitivity
may require dose adjustment
Corticosteroids (prednisone)
opposing anabolic/catabolic effects; long-term corticosteroid use blunts androgen receptor signalling
Other anabolic steroids
additive HPG suppression, hepatic stress (with oral 17-AA stacks), cardiovascular risk
Aromatase inhibitors (anastrozole, letrozole): commonly co-researched to control oestradiol
over-suppression of E2 causes joint pain, lipid dysregulation, libido loss
5-alpha-reductase inhibitors (finasteride, dutasteride): block DHT conversion
reduces DHT-mediated side effects but may impair libido/sexual function research outcomes
Alcohol (chronic use)
impairs Leydig cell function and aromatase regulation; hepatic stress when combined with oral AAS
Cocaine / methamphetamine: severe cardiovascular strain alongside testosterone-driven haematocrit elevation and lipid changes
significant risk profile
MDMA
cardiovascular and serotonergic strain compounded with anabolic load
Opioids (chronic use): independently suppress HPG axis
confounds research interpretation; long-term opioid users often present with low endogenous testosterone
Cannabis (heavy chronic use)
documented reductions in LH pulsatility and endogenous testosterone in research literature
Competitive sports anti-doping: WADA-prohibited
any detection triggers sanctions
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.